Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 3, 1998, Pages 257-268

  Kashuba, Angela D M ^b   Nafziger, Anne N ^b   Kearns, Gregory L ^b   Leeder, J Steven ^b   Gotschall, Russell ^b   Rocci Jr , Mario L ^b   Kulawy, Robert W ^b   Beck, Debra J ^b   Bertino Jr , Joseph S ^a  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; CAFFEINE; CYTOCHROME P450; DEBRISOQUINE 4 HYDROXYLASE; DEXTROMETHORPHAN; FLUVOXAMINE MALEATE; MIDAZOLAM; PHENACETIN O DEETHYLASE; ROBITUSSIN PEDIATRIC SOLUTION; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DROWSINESS; DRUG CLEARANCE; DRUG EFFECT; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FOLLICULAR PHASE; HEART PALPITATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUTEAL PHASE; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SLEEP DISORDER; STEADY STATE;

ACETYLTRANSFERASES; ADULT; ANTI-ANXIETY AGENTS; ANTITUSSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; FEMALE; FLUVOXAMINE; GENOTYPE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDAZOLAM; OXIDOREDUCTASES, N-DEMETHYLATING; PHENOTYPE; REFERENCE VALUES; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; XANTHINE OXIDASE;

EID: 0031664102     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90174-6     Document Type: Article

References (42)

1. Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Pharmacol 1995;15:387-98.
2. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993;24: 203-20.
3. Perucca E, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1994;27:175-90.
4. Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995;58:399-403.
5. Jeppesen U, Loft S, Poulsen HE, Brosen K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996;6:213-22.
6. Carrillo JA, Dahl ML, Svensson JO, Aim C, Rodriguez I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996;60:183-90.
7. Spigset O, Granberg K, Haag S, Norstrom A, Dahlqvist R. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol 1997;52:129-33.
8. Xu ZH, Xie HG, Z HH. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 1996;42:518-21.
9. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 1995;31:347-53.
10. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
11. Rasmussen BB, Maenpaa J, Pelkonen O, Loft S, Pousen HE, Lykkesfeldt J, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995;39:151-9.
12. Pastrakuljic A, Tang BK, Roberts EA, Kalow W. Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem Pharmacol 1997;53:531-8.
13. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994;46:35-9.
14. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors of cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
15. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278-83.
16. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997;32(suppl 1):1-21.
17. DeVane CL. Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 1992;53(suppl 2):13-20.
18. Corso DM, Pucino F, DeLeo JM, Calis KA, Gallelli JF. Development of a questionnaire for detecting potential adverse drug reactions. Ann Pharmacother 1992;26:890-6.
19. Evans WE, Relling MV, Petros WP, Meyer WH, Mirro J Jr, Crom WR. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 1989;45:568-73.
20. Park YH, Kullberk MD, Hinsvark ON. Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high performance liquid chromatography. J Pharm Sci 1984;73:24-9.
21. Lam YW, Rodriguez SY High performance liquid chromatography determination of dextromethorphan and dextrorphan for oxidation phenotyping by fluorescence and ultraviolet detection. Ther Drug Monit 1993;15:300-4.
22. Daly AK, Brockmoeller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996;6:193-201.
23. Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997;7:193-202.
24. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-95.
25. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983;33:591-602.
26. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987;42:157-65.
27. Grant DM, Tang BK, Campbell ME, Kalow W. Effect of allopurinol on caffeine disposition in man. Br J Clin Pharmacol 1986;21:454-8.
28. Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 1991;49: 648-57.
29. Schmid B, Birder J, Presig R, Kupfer A. Polymorphic dextromethorphan metabolism: cosegregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985;38:618-24.
30. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, et al. Use of midazolam as a human cytochrome P4503A probe; I: in vitro-in vivo correlalions in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-56.
31. Tanswell P, Koup J. Topfit: a PC based pharmacokinetic/pharmacodynamic data analysis program. Int J Clin Pharmacol Ther Toxicol 1993;31:514-20.
32. Systat user's guide. Evanston (IL): SYSTAT Intelligent Software; 1990.
33. Preskorn SH, Magnus RD. Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull 1994;30:251-9.
34. Otton SV, Ball SE, Cheung SW, Inaba T, Sellers EM. Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine and other 5HT uptake inhibitors. Clin Pharmacol Ther 1994;55:141.
35. Kasper S, Dotsch M, Kick H, Vieira A, Moller HJ. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neurophychopharmacol 1993;3:13-21.
36. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other serotonin-reuptake- inhibitor antidepressants. J Clin Psychopharmacol 1995; 15:125-31.
37. Perruca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S, et al. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994;56:471-6.
38. Ozdemir V, Naranjo CA, Shulman RW, Herrmann N, Sellers EM, Kalow W. An in vivo comparison of paroxetine and fluvoxamine: effects on CYP1A2 and CYP2D6 activities [abstract]. Clin Pharmacol Ther 1997;61:177.
39. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994;46:35-9.
40. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 1996;16:104-12.
41. Devine BJ. Gentamicin pharmacokinetics. Drug Intell Clin Pharm 1974;8:650-5.
42. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.